Immunology and inflammation

News

J&J adds rare disease wAIHA to Imaavy's potential uses

Johnson & Johnson's 'Swiss army knife' drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA.

News

Lilly wins new FDA approval for eczema drug Ebglyss

Lilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.

News

Bristol Myers Squibb and Hengrui Pharma logos

BMS signs $15.2bn R&D alliance with China's Hengrui

Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.

News

Autoimmune disease biotech Odyssey sets terms for $225m IPO

After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.

News

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

News

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

J&J adds rare disease wAIHA to Imaavy's potential uses

Lilly wins new FDA approval for eczema drug Ebglyss

BMS signs $15.2bn R&D alliance with China's Hengrui

Autoimmune disease biotech Odyssey sets terms for $225m IPO

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Where others missed, AZ's IL-33 drug hits the mark in COPD

UK offers meningitis jab to young people after outbreak

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks